Abstract
The lung is a vital organ that houses the alveoli, which is where gas exchange takes place. The COVID-19 illness attacks lung cells directly, creating significant inflammation and resulting in their inability to function. To return to the nature of their job, it may be essential to rejuvenate the afflicted lung cells. This is difficult because lung cells need a long time to rebuild and resume their function. Biopolymeric particles are the most effective means to transfer developing treatments to airway epithelial cells and then regenerate infected lung cells, which is one of the most significant symptoms connected with COVID-19. Delivering biocompatible and degradable natural biological materials, chemotherapeutic drugs, vaccines, proteins, antibodies, nucleic acids, and diagnostic agents are all examples of these molecules‘ usage. Furthermore, they are created by using several structural components, which allows them to effectively connect with these cells. We highlight their most recent uses in lung tissue regeneration in this review. These particles are classified into three groups: biopolymeric nanoparticles, biopolymeric stem cell materials, and biopolymeric scaffolds. The techniques and processes for regenerating lung tissue will be thoroughly explored.
Highlights
COVID-19, a rapidly evolving coronavirus, needs urgent therapy development
A new generation of medications is urgently required to counterbalance the hyperactive immune response, retain alveolar function, and cure lung and systemic organ damage resulting from COVID-19
Poor lung circulation, scarring, and airway occlusion have been linked to COVID-19 exposure
Summary
New immunosuppressive medications are urgently needed to preserve alveolar function and repair lung and systemic organ damage. COVID-19‘s genetic structure, current transmission mechanisms and control strategies, etiology, clinical presentation, and lung effect have all been examined [1]. These exosomes generated by immunoregulatory DCs include an abundance of immunoregulatory proteins, compelling us to study their biodistribution to vital organs following intravenous injection [2]. Two new LNP formulations have been developed and evaluated for siRNA therapeutic delivery to the lungs, an organ severely damaged by SARS-CoV-2 infection. Injecting siRNA into these LNPs significantly reduced the viral load in the lungs and increased animal survival [3]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
